ProCE Banner Activity

Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges

Multimedia
In this on-demand Webcast of a CCO symposium at CHEST 2019, a multidisciplinary panel of expert faculty, including a medical oncologist, a radiation oncologist, and a pulmonologist, review and discuss the latest data on optimal integration of immune checkpoint inhibitors into the care of patients with stage III NSCLC.

Released: November 20, 2019

Expiration: November 18, 2020

Share

Faculty

Kristin Higgins

Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Gerard A. Silvestri

Gerard A. Silvestri, MD, MS

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies, including whether to pursue resection, for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients with stage III NSCLC most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Identify subsets of patients with stage III NSCLC most likely to benefit from pembrolizumab
  • Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients
  • Manage immune-mediated adverse events with the use of automated decision support resources and guidelines

Program Director Disclosure

Program Director

Gerard A. Silvestri, MD, MS

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina

Gerard A. Silvestri, MD, MS, has disclosed that he has received consulting fees from AstraZeneca.

Faculty Disclosure

Primary Author

Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Kristin Higgins, MD, has disclosed that she has received consulting fees from AstraZeneca and Varian and funds for research support from Reflexion.

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, has disclosed that he has received funds for research support from AstraZeneca, Genentech, Novartis, and Spectrum; consulting fees from Genentech, Lilly, and Novartis; and fees for non-CME/CE services from AstraZeneca, Bayer, and Genentech.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.